Document Detail


Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
MedLine Citation:
PMID:  3315604     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
90 patients were enrolled into this preliminary multicentre study of the efficacy and safety of 30 units intravenous anisoylated plasminogen streptokinase activator complex (APSAC) compared with placebo in patients with acute myocardial infarction. 45 patients received APSAC and 45 placebo; the groups were similar for age, weight and site of infarction. There were significantly more women treated with APSAC (p less than 0.02). The mean time to treatment was 3.3 hours after symptoms of myocardial infarction for APSAC and 3 hours for placebo. The 30-day mortality was 7 patients in the placebo group and 1 in the APSAC group (p = 0.058). Adverse events were generally minor and were of similar overall frequency in both groups. There were more haemorrhagic events with APSAC, from which all patients recovered, and more cardiovascular events with placebo including 2 deaths from cardiogenic shock. APSAC showed a trend towards a reduction in 30-day mortality. Experience from this study has led to the initiation of the APSAC in myocardial infarction multicentre mortality study (AIMS).
Authors:
D G Julian; L S Borthwick; D Reid; K P Jennings; R J Wainwright; J C Rodger; D Wood; W S Phillips
Related Documents :
8391984 - Preserved oxidative activity and chemotaxis of circulating neutrophils in patients with...
17916934 - Increases of calcium, phosphorus, and magnesium in both the right and left fibrous trig...
6377564 - Acylated streptokinase--plasminogen complex in patients with acute myocardial infarction.
6488304 - Intravenous versus intracoronary streptokinase for acute transmural myocardial infarction.
2347124 - Unrecognized left ventricular dysfunction in an apparently healthy cocaine abuse popula...
22121044 - The prognostic role of mitral regurgitation after primary percutaneous coronary interve...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  261-7     Citation Subset:  IM    
Affiliation:
1 Freeman Hospital, Newcastle upon Tyne.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anistreplase
Blood Pressure / drug effects
Clinical Trials as Topic
Female
Fibrinolytic Agents / adverse effects,  therapeutic use*
Hemorrhage / chemically induced
Humans
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction / drug therapy*,  mortality
Plasminogen / adverse effects,  therapeutic use*
Random Allocation
Streptokinase / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase act...
Next Document:  Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myo...